Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2732695 | 0.86 | HDAC1 (0.74) | HDAC1KCNH2HDAC3HDAC2HDAC8 | |
| SCHEMBL2732693 | 0.86 | HDAC1 (0.74) | HDAC1KCNH2HDAC3HDAC2HDAC8 | |
| SCHEMBL31192 | 0.86 | HDAC1 (0.74) | HDAC1KCNH2HDAC3HDAC2HDAC8 | |
| SCHEMBL6898993 | 0.84 | HDAC1 (0.77) | HDAC1KCNH2HDAC3HDAC2HDAC8 | |
| SCHEMBL725030 | 0.78 | HDAC1 (0.91) | HDAC1KCNH2HDAC3HDAC2HDAC8 | |
| SCHEMBL1486885 | 0.78 | HDAC1 (1.00) | HDAC1KCNH2HDAC3HDAC2HDAC8 | |
| SCHEMBL6866262 | 0.78 | HDAC1 (1.00) | HDAC1KCNH2HDAC3HDAC2HDAC8 | |
| SCHEMBL1486883 | 0.78 | HDAC1 (1.00) | HDAC1KCNH2HDAC3HDAC2HDAC8 | |
| SCHEMBL1486881 | 0.78 | HDAC1 (1.00) | HDAC1KCNH2HDAC3HDAC2HDAC8 | |
| SCHEMBL725029 | 0.78 | HDAC1 (0.91) | HDAC1KCNH2HDAC3HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060009-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885KCNH2 3187/4885HDAC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.